

comprising administering to the individual cyclosporin or an analog thereof in combination with a tumor necrosis factor alpha antagonist, in therapeutically effective amounts.

16. (Amended) A method of Claim 15 wherein the tumor necrosis factor alpha antagonist is an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof.

18. (Amended) A method of Claim 15 wherein the tumor necrosis factor alpha antagonist is a receptor molecule which binds to tumor necrosis factor alpha.

19. (Amended) A method of Claim 18 wherein the receptor molecule is a tumor necrosis factor alpha receptor/immunoglobulin G fusion protein.

20. (Amended) A method of Claim 15 wherein the tumor necrosis factor alpha antagonist prevents or inhibits tumor necrosis factor alpha synthesis, tumor necrosis factor alpha release or its action on target cells.

21. (Amended) A method of Claim 20 wherein the tumor necrosis factor alpha antagonist is a phosphodiesterase inhibitor.

23. (Amended) A method [for] of treating [or preventing] Crohn's disease in an individual in need thereof comprising administering to the individual cyclosporin or an analog thereof in combination with a tumor necrosis factor alpha antagonist, in therapeutically effective amounts.

24. (Amended) A method of Claim 23 wherein the tumor necrosis factor alpha antagonist is an anti-tumor necrosis factor alpha antibody or antigen-binding fragment thereof.